Vestcor Inc’s BridgeBio Pharma BBIO Stock Holding History

Vestcor Inc’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-73,849	Closed	-$1.27M	–	1296
2023 Q2	$1.27M	Buy	+73,849	New	+$1.11M	0.05%	372

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Vestcor Inc's BBIO Position: Q3 2023 in Review

Vestcor Inc sold out of BridgeBio Pharma (BBIO) in Q3 2023, closing a stake of 73,849 shares — an estimated $1.27M sold.

Vestcor Inc first reported a position in BBIO in Q2 2023 and held it in 1 quarter. The position peaked at $1.27M in Q2 2023. 221 funds tracked by Wall St. Rank hold BBIO as of Q3 2023.

Vestcor Inc reported no remaining BridgeBio Pharma position as of Q3 2023 after selling out during the quarter.
Vestcor Inc sold 73,849 BridgeBio Pharma shares in Q3 2023, an estimated $1.27M.
Vestcor Inc first reported a position in BridgeBio Pharma in Q2 2023 and held it in 1 quarter.
Vestcor Inc's BridgeBio Pharma position peaked at $1.27M in Q2 2023.
221 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2023.

Based on Vestcor Inc's 13F filing for Q3 2023, filed 14 Nov 2023.